Mobile Medication Adherence Platform for Buprenorphine (MAP4BUP): A Phase I Feasibility, Usability and Efficacy Pilot Randomized Clinical Trial

Overview

Journal Drug Alcohol Depend

Publisher Elsevier

Specialty Psychiatry

Date 2024 Feb 2

PMID 38306822

Authors

Sterling M McPherson

Crystal L Smith

Luke Hall

Andre Q Miguel

Theresa Bowden

Abigail Keever

Alex Schmidt

Katie Olson

Nicole Rodin

Michael G McDonell

John M Roll

Jeff LeBrun

Affiliations

Soon will be listed here.

Abstract

Background/aim: Poor medication adherence is one of the main barriers to the long-term efficacy of buprenorphine/naloxone (BUP/NAL). The aims of this pilot investigation were to examine if a Bluetooth-enabled pill cap and mobile application is a feasible, usable tool for increasing BUP/NAL adherence among people with an opioid use disorder.

Methods: This pilot randomized clinical trial (RCT; total n = 41) lasted 12 weeks and was conducted in two office-based BUP/NAL provider locations in Spokane, WA and Coeur d'Alene, ID from January 2020 to September of 2021 with an 11-month gap due to COVID-19. Patients receiving BUP/NAL who consented to participate were randomized to receive the pill cap device (PLY group; n = 19) or a service as usual (SAU group; n = 22) group that included an identical but inactive cap for their bottle. The PLY group received reminders via text and voice, and the support of a "helper" (e.g., friend) to monitor pill cap openings.

Results: Most participants in PLY group found the device both feasible (92.86 %) and usable (78.57 %). Most participants liked using the device (92.86 %) and were satisfied with the device (85.71 %). While not statistically different from one another, medication adherence per the Medication Possession Ratio was 75 % in the SAU group and 84 % in the PLY group. Pill cap openings were significantly higher in the PLY group with an average of 91.8 openings versus the SAU group's average of 56.7 (p < 0.05).

Conclusion: The devices was feasible, usable, and patients had high levels of satisfaction. The device was associated with increased pill openings.

References

Rosenblum A, Cleland C, Fong C, Kayman D, Tempalski B, Parrino M . Distance traveled and cross-state commuting to opioid treatment programs in the United States. J Environ Public Health. 2011; 2011:948789. PMC: 3136171. DOI: 10.1155/2011/948789. View

Ruetsch C, Tkacz J, Nadipelli V, Brady B, Ronquest N, Un H . Heterogeneity of nonadherent buprenorphine patients: subgroup characteristics and outcomes. Am J Manag Care. 2017; 23(6):e172-e179. View

Velez F, Anastassopoulos K, Colman S, Shah N, Kauffman L, Murphy S . Reduced Healthcare Resource Utilization in Patients with Opioid Use Disorder in the 12 Months After Initiation of a Prescription Digital Therapeutic. Adv Ther. 2022; 39(9):4131-4145. PMC: 9402736. DOI: 10.1007/s12325-022-02217-y. View

Hadland S, Park T, Bagley S . Stigma associated with medication treatment for young adults with opioid use disorder: a case series. Addict Sci Clin Pract. 2018; 13(1):15. PMC: 5937046. DOI: 10.1186/s13722-018-0116-2. View

Fareed A, Eilender P, Ketchen B, Buchanan-Cummings A, Scheinberg K, Crampton K . Factors affecting noncompliance with buprenorphine maintenance treatment. J Addict Med. 2014; 8(5):345-50. DOI: 10.1097/ADM.0000000000000057. View

Fudala P, Bridge T, Herbert S, Williford W, Chiang C, Jones K . Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003; 349(10):949-58. DOI: 10.1056/NEJMoa022164. View

Park H, Kang H, Kim S, Singh-Carlson S . Effect of a Smart Pill Bottle Reminder Intervention on Medication Adherence, Self-efficacy, and Depression in Breast Cancer Survivors. Cancer Nurs. 2021; 45(6):E874-E882. PMC: 9584037. DOI: 10.1097/NCC.0000000000001030. View

Dayal P, Balhara Y . A naturalistic study of predictors of retention in treatment among emerging adults entering first buprenorphine maintenance treatment for opioid use disorders. J Subst Abuse Treat. 2017; 80:1-5. DOI: 10.1016/j.jsat.2017.06.004. View

Tkacz J, Volpicelli J, Un H, Ruetsch C . Relationship between buprenorphine adherence and health service utilization and costs among opioid dependent patients. J Subst Abuse Treat. 2013; 46(4):456-62. DOI: 10.1016/j.jsat.2013.10.014. View

10.

Williams A, Aronowitz S, Gallagher R, Behar E, Gray Z, Bisaga A . A Virtual-First Telehealth Treatment Model for Opioid Use Disorder. J Gen Intern Med. 2022; 38(3):814-816. PMC: 9714767. DOI: 10.1007/s11606-022-07955-x. View

11.

Ling W, Shoptaw S, Goodman-Meza D . Depot Buprenorphine Injection In The Management Of Opioid Use Disorder: From Development To Implementation. Subst Abuse Rehabil. 2019; 10:69-78. PMC: 6889966. DOI: 10.2147/SAR.S155843. View

12.

Velez F, Colman S, Kauffman L, Ruetsch C, Anastassopoulos K . Real-world reduction in healthcare resource utilization following treatment of opioid use disorder with reSET-O, a novel prescription digital therapeutic. Expert Rev Pharmacoecon Outcomes Res. 2020; 21(1):69-76. DOI: 10.1080/14737167.2021.1840357. View

13.

KRASNOFF A . Differences between alcoholics who complete or withdraw from treatment. J Stud Alcohol. 1976; 37(11):1666-71. DOI: 10.15288/jsa.1976.37.1666. View

14.

Stringfellow E, Lim T, Humphreys K, DiGennaro C, Stafford C, Beaulieu E . Reducing opioid use disorder and overdose deaths in the United States: A dynamic modeling analysis. Sci Adv. 2022; 8(25):eabm8147. PMC: 9232111. DOI: 10.1126/sciadv.abm8147. View

15.

Muruganandam P, Shukla L, Sharma P, Kandasamy A, Chand P, Murthy P . 'Too little dose - too early discontinuation?'-Effect of buprenorphine dose on short term treatment adherence in opioid dependence. Asian J Psychiatr. 2019; 44:58-60. DOI: 10.1016/j.ajp.2019.07.030. View

16.

Hser Y, Liang D, Lan Y, Vicknasingam B, Chakrabarti A . Drug Abuse, HIV, and HCV in Asian Countries. J Neuroimmune Pharmacol. 2016; 11(3):383-93. DOI: 10.1007/s11481-016-9665-x. View

17.

Zemore S . The effect of social desirability on reported motivation, substance use severity, and treatment attendance. J Subst Abuse Treat. 2011; 42(4):400-12. PMC: 3296824. DOI: 10.1016/j.jsat.2011.09.013. View

18.

Kinsky S, Houck P, Mayes K, Loveland D, Daley D, Schuster J . A comparison of adherence, outcomes, and costs among opioid use disorder Medicaid patients treated with buprenorphine and methadone: A view from the payer perspective. J Subst Abuse Treat. 2019; 104:15-21. DOI: 10.1016/j.jsat.2019.05.015. View

19.

Peter S, Murphy J, Witkiewitz K, Hand S, Thomas F, Johnson K . Use of a sequential multiple assignment randomized trial to test contingency management and an integrated behavioral economic and mindfulness intervention for buprenorphine-naloxone medication adherence for opioid use disorder. Trials. 2023; 24(1):237. PMC: 10061866. DOI: 10.1186/s13063-023-07102-9. View

20.

Volkow N, Frieden T, Hyde P, Cha S . Medication-assisted therapies--tackling the opioid-overdose epidemic. N Engl J Med. 2014; 370(22):2063-6. DOI: 10.1056/NEJMp1402780. View